Tyra Biosciences Inc To Discuss Expansion of TYRA-300 Development Call Transcript
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Tyra Biosciences Conference Call to discuss the expansion of the development of TYRA-300. As a reminder, this conference call is being recorded.
Now I would like to turn the call over to Amy Conrad from Investor Relations. Please go ahead.
Thank you, Rob. Good morning, everyone, and thank you for joining us. With me today from Tyra are Todd Harris, Chief Executive Officer; Ron Swanson, Chief Scientific Officer; and Hiroomi Tada, Chief Medical Officer. Also on today's call are Dr. Michael Bober, Medical Director of the Skeletal Dysplasia Program at Nemours Children's Hospital, Delaware; and Dr. Laurence Legeai-Mallet from the Imagine Institute in Paris, France.
Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements concerning Tyra's future expectations, plans, prospects, strategy and performance, which constitute forward-looking statements for the purposes of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
